| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/BMT.2017.232 |
| P698 | PubMed publication ID | 29058697 |
| P2093 | author name string | Y Wang | |
| D Bensoussan | |||
| L Reppel | |||
| V Decot | |||
| C Qian | |||
| A Campidelli | |||
| M D'aveni | |||
| P2860 | cites work | Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines | Q26745838 |
| Antiviral T-cell therapy | Q27028006 | ||
| Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation | Q33375408 | ||
| Adoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation | Q33410361 | ||
| T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study | Q33456341 | ||
| Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease | Q33456742 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial. | Q33647028 | ||
| Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. | Q34273968 | ||
| Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation | Q34312922 | ||
| Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. | Q34450754 | ||
| TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells | Q34499653 | ||
| Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial | Q34623991 | ||
| A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation | Q35012553 | ||
| Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach | Q35139240 | ||
| Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections | Q35836837 | ||
| Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation | Q35849338 | ||
| Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia | Q35958223 | ||
| Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers | Q36403280 | ||
| Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. | Q36766875 | ||
| Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation | Q36962653 | ||
| T cells for viral infections after allogeneic hematopoietic stem cell transplant | Q37058107 | ||
| Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation | Q37316282 | ||
| Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant | Q37316838 | ||
| Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) | Q37450543 | ||
| The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness | Q37527942 | ||
| Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy | Q37630991 | ||
| How I treat adenovirus in hematopoietic stem cell transplant recipients | Q37788461 | ||
| Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections | Q38797555 | ||
| Immunotherapy for transplantation-associated viral infections | Q39382670 | ||
| T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant | Q40168886 | ||
| Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. | Q40370932 | ||
| T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections | Q40572663 | ||
| Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. | Q40621588 | ||
| Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation | Q40726021 | ||
| Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy | Q40732151 | ||
| Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-γ Immunomagnetic Selection. | Q40881129 | ||
| Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. | Q41010586 | ||
| Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. | Q41524284 | ||
| Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation | Q41978755 | ||
| First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation | Q42226051 | ||
| Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy | Q43102148 | ||
| Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease | Q43273411 | ||
| Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation | Q43406230 | ||
| Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells | Q44013424 | ||
| Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. | Q44814759 | ||
| Rapid salvage treatment with virus-specific T cells for therapy-resistant disease | Q45356159 | ||
| Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation | Q45370775 | ||
| Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells | Q45400082 | ||
| Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation | Q45415157 | ||
| Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells | Q45730808 | ||
| Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. | Q45744882 | ||
| Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). | Q45760718 | ||
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals | Q45862722 | ||
| Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation | Q46971157 | ||
| BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation | Q47927972 | ||
| T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? | Q50778923 | ||
| Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation | Q60455157 | ||
| Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation | Q60455163 | ||
| Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update | Q64378254 | ||
| Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 | ||
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-10-23 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. |
| Q92857814 | Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation |
| Q61817999 | Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation |
| Q90598401 | Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy |
Search more.